02:48 AM EDT, 08/27/2026 (MT Newswires) -- AstraZeneca (AZN.L, AZN.ST) and Amgen's Tezspire showed statistically significant and clinically meaningful improvements in the symptoms of eosinophilic esophagitis in a late-stage study, , according to a Thursday release. The phase 3 Crossing trial evaluated the efficacy and safety of Tezspire in patients aged 12 to 80 years with symptomatic and histologically active eosinophilic esophagitis. It was administered subcutaneously every four weeks in the study, which had co-primary endpoints of histologic remission and dysphagia symptoms. The companies plan to share the full trial results with regulatory agencies and at an upcoming medical meeting. Tezspire, or tezepelumab, is currently approved for severe asthma and chronic rhinosinusitis with nasal polyps in the US, European Union, China and Japan. Studies evaluating the drug in chronic obstructive pulmonary disease are also ongoing.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.